The Global Preimplantation Genetic Diagnosis Market currently holds a value of USD 61.6 Mn in 2025 yet analysts predict it will grow to USD 104.2 Mn by 2032 while demonstrating a compound annual growth rate (CAGR) of 7.8% between 2025 and 2032.
To learn more about this report, Download Free Sample
The preimplantation genetic diagnosis market will undergo substantial market growth because of rising infertility conditions and rising parental age and increased awareness about inherited diseases. During IVF procedures PGD enables the selection of embryos with no genetic health problems to decrease the transmission of serious inherited diseases. Adoption faces challenges because of its elevated costs and moral issues that surface around selecting embryo genders and discarding excess embryos in certain parts of the world.
|
Current Events |
Description and its impact |
|
Insurance Policy Shifts
|
|
|
Increased Parental Age
|
|
|
Technological Innovations in Genetic Testing |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The cost of PGD treatment worldwide falls within a range of USD 10,000 to USD 15,000 per cycle. A combination of IVF treatment with hormone therapy and embryo freezing and laboratory expenses increases total costs beyond USD 25,000 per attempt. Insurance-free patients and those who do not obtain government financial assistance experience significant financial strain because of these elevated PGD fees.
PGD obtains varied reimbursement standards among different countries throughout the world. American private health insurers might pay for PGD where a genetic disorder exists but they typically deny payment when people seek genetic testing as a choice. PGD medical treatment in the United Kingdom receives NHS coverage yet only in cases where patients carry strong physiological risks for transmitting serious hereditary disorders.
The Preimplantation Genetic Diagnosis Market demonstrates dominance by the Chromosomal Abnormalities segment with an estimated 30.7% market share in 2025. Maternal age elevation together with the rising incidence of trisomy 13, 18 and 21 disorders propels the preimplantation genetic diagnosis market growth. The main purpose of PGD is its ability to detect genetic anomalies before embryo implantation to help fertility specialists choose only balanced embryos which decreases miscarriage rates while boosting IVF success outcomes.
PGD testing is a standard procedure in UK clinics for detecting Down syndrome (trisomy 21) within the population of older women over age 35 due to their higher risk of chromosomal disorders. The National Health Service (NHS) reports that IVF procedures where genetic testing including PGD chromosomal analysis are performed have continually increased in number since 2020. Fertility centres implement advanced technologies while supporting increasing patient numbers from older parents.
Specialized embryo testing activities through Diagnostic Laboratories facilities will drive their market share to reach 40.71% by 2025. Advanced genomic equipment and certified technicians running single-cell analysis and comprehensive genetic profiling and AI-supported sequencing exist within these diagnostic laboratories. External laboratories receive PGD procedure orders from North American and Asian fertility clinics because the clinics want to minimize their expenditures and enhance their operational performance. In 2024 CooperSurgical began providing PGT-A screening services powered by artificial intelligence through telehealth systems to medical clinics across the United States and Southeast Asia to enhance individualized reproductive services access. Igenomix enhanced its genomic testing services across India and Latin America through real-time data sharing and remote reporting which directed clinic-lab collaboration. This segment grows more due to expanding telehealth industry which lets fertility providers provide premium PGD services instead of constructing their own onsite capabilities.
To learn more about this report, Download Free Sample
Preimplantation Genetic Diagnosis Market will continue to lead globally through North America which will occupy 41.7% of total 2025 market revenues. The United States leads the regional demand for PGD services because ART is commonly practiced and genetics testing is readily accessible and insurance coverage exists for such treatments. The Centers for Disease Control and Prevention (CDC) reports 300,000 ART cycles were performed within the United States in 2022 along with PGD integration in many clinical protocols. The state of California drives innovation through its home-based companies Illumina Inc. and Natera Inc. while these businesses maintain their support for high-throughput sequencing and single-cell diagnostic platforms. The high-end medical facilities at NYU Langone and Stanford Health provide PGD services within their complete IVF treatment programs showing the advanced healthcare system and easy access points throughout the region.
The Chinese population seeks Preimplantation Genetic Diagnosis (PGD) services more often in Beijing and Shanghai and public-private collaborations are establishing broader access to genetic testing facilities. Public health authorities through Healthy China 2030 actively support reproductive genetics and preventative medical care by adopting PGD as their strategic approach for long-term healthcare improvement. Both public hospitals and private fertility clinics develop expanded infrastructure to fulfill increasing patient demand that originates from Chinese residents and incoming patients seeking fertility treatment.
The European market for PGD services continues to expand in a stable manner through supportive healthcare regulatory systems that bankroll IVF programs. The Human Fertilization and Embryology Authority (HFEA) in the United Kingdom maintains detailed licensing framework for PGD clinics. The IVF protocols at Guy’s and St Thomas’ Hospital in London include full chromosomal screening as an essential service. Spain together with Belgium offer legal and inexpensive healthcare services to medical tourists through their modern healthcare infrastructure and supportive reproductive policies, further escalating the preimplantation genetics market share.
The Latin American countries Brazil and Mexico show rising PGD utilization levels because their private infertility services continue to grow at the same time their medical services become more affordable. The Brazilian governmental Mother Baby program through the Ministry of Health helps expand both maternal care and prenatal diagnostics. Mexico has observed increased accessibility of IVF with PGD due to public-private partnerships including Instituto Vida that particularly benefit major cities across Mexico City and Guadalajara. Genetic diagnostics find growing long-term demand throughout the region because of rising middle-class status and improved understanding of inherited disorders.
The United States maintains a leading position in the market due to its robust healthcare system together with supportive medical insurance policies and increasing acceptance of genetic screening tests from the public. The PGD procedures operated by both CCRM (Colorado Center for Reproductive Medicine) and Stanford Health exist as standardized IVF protocol components to enhance patient outcomes.
The market for Preimplantation Genetic Diagnosis is launching as a rapid growth sector in China. The Chinese Preimplantation Genetic Diagnosis Market Demand continues to grow because of fast healthcare infrastructure development alongside government-backed health programs and the expansion of private IVF facilities such as Jinxin Fertility Group. The future growth potential for the Preimplantation Genetic Diagnosis Market Demand is strong despite regulatory uncertainties because China has large patient populations and growing numbers of fertility tourists.
The implementation of Preimplantation Genetic Diagnosis (PGD) encounters multiple practical and structural limitations because of high costs along with different policies and societal resistance to the procedure. American middle-class families cannot afford the PGD procedure because each cycle costs USD 10,000 to USD 15,000. The American Society for Reproductive Medicine (ASRM) reports that most private insurers exclude PGD coverage unless it is used for detecting diagnosed inherited disease. Patients in New York need to show existing genetic risks in order to cover PGD services from their insurance but can occasionally receive partial IVF reimbursement through their plans.
The traditional principles in Saudi Arabia together with religious guidelines in Malaysia result in minimal PGD service demands despite existing healthcare systems. Several Riyadh and Jeddah fertility clinics provide PGD technical capabilities per the Middle East Fertility Society Journal (2021) but many patients refrain from using the service because of religious concerns regarding destroyed embryos.
The discrepancies between international laws regarding regulation make it even harder for patients to access services. The Human Fertilization and Embryology Authority (HFEA) of the United Kingdom needs all PGD clinics to secure particular licenses while implementing open procedures for embryo selection. Mexico maintains no uniform national PGD oversight at the federal level so its clinics follow different ethical boards that produce varying service quality and genetic testing methods.
Preimplantation Genetic Diagnosis Market is adopting personalized family planning as a primary trend since individuals and couples want to manage hereditary risks and schedule parenthood. PGD serves medical exactness to bring family aspirations into harmony with diagnostic screening of genetic abnormalities. Women aged 30 to 40 at U.S. fertility clinics such as CCRM (Colorado Center for Reproductive Medicine) have started using PGD to manage their reproduction risks while postponing pregnancy according to their plans.
Singaporean clinic Virtus Fertility Centre creates individual PGD plans for couples at risk of hereditary disorders so they can choose healthy embryos before embryo transfer. The delayed childbearing habits among professional women lead them to seek PGD as a technology for safeguarding their reproductive health outcomes, thereby adding to the Preimplantation Genetic Diagnosis Market share.
Fast-growing economies are establishing themselves as major market growth sectors because they enhance their investments in sophisticated maternal health care together with fertility treatments. The market expansion has potential due to favorable demographics together with healthcare conditions in countries such as India and Brazil and Mexico. The United Nations Population Fund (UNFPA, 2023) reports these nations have more than 60% youth populations that will sustain long-term demand for reproductive technologies and fertility treatments. Hyderabad along with Ahmedabad demonstrates increasing PGD demand in India because of affordable services and fertility clinic innovation among the local medical facilities. Massive national programs which raise fertility knowledge and perform genetic tests have pushed accessibility to new heights. The Brazilian Ministry of Health supports affordable fertility assistance through its “Mother Baby” program which helps speed up PGD technology acceptance. México increases its IVF market presence by merging public health services with private fertility clinics like Instituto Vida which enables both national extension and local implementation of PGD services. The current advancements represent a substantial chance for personalized reproductive medicine to expand its reach and accessibility in the developing world.
The Preimplantation Genetic Diagnosis (PGD) technology progresses rapidly which helps medical treatments become safer as well as accessible and smarter for patient populations throughout the world. The year 2024 marked the arrival of AIVF and Life Whisperer as the two companies that introduced AI technology into IVF laboratories through the use of time-lapse imaging to evaluate embryo viability. Since AI platforms operate in embryology labs they enable identification of healthy embryos while causing no harm to the embryos through biopsy and ensuring a precise and minimally invasive procedure.
GenEmbryomics conducted its first trials of single-cell sequencing through droplet microfluidics technology during that year. The method enables specialized genetic analysis of embryonic cells without harming or damaging the embryo. These developments mark an important advance in creating diagnostic methods that preserve embryonic wellbeing.
Takara Bio delivered to the market its microfluidic transduction enhancer in May 2024 as a new laboratory device that automates embryo research material transfers. The microfluidic transduction enhancer has already introduced to Asian and U.S. research centers for helping laboratories achieve better accuracy while decreasing human mistakes. These revolutionary technologies create conditions for next-generation preventive reproductive care which enhances PGD efficiency and precision while increasing accessibility across the board.
Preimplantation Genetic Diagnosis Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 61.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.8% | 2032 Value Projection: | USD 104.2 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
PerkinElmer, Inc., Genea Limited, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Quest Diagnostics Incorporated, Illumina, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), LabCorp of America Holdings (Laboratory Corporation of America), Natera, Inc., Oxford Gene Technology, California Pacific Medical Center, Good Start Genetics, Inc., Invitae Corporation, F. Hoffmann-La Roche AG, Progenesis |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
